Literature DB >> 28062087

Does an integrated boost increase acute toxicity in prone hypofractionated breast irradiation? A randomized controlled trial.

Leen Paelinck1, Akos Gulyban2, Ferenc Lakosi2, Tom Vercauteren1, Werner De Gersem3, Bruno Speleers4, Christel Monten3, Thomas Mulliez1, Patrick Berkovic2, Annick van Greveling1, Frederik Decoster1, Philippe Coucke2, Wilfried De Neve3, Liv Veldeman5.   

Abstract

BACKGROUND AND
PURPOSE: The safety of a simultaneous integrated boost (SIB) in combination with prone hypofractionated whole-breast irradiation (WBI) was investigated.
MATERIALS AND METHODS: 167 patients were randomized between WBI with a sequential boost (SeB) or SIB. All patients were treated in prone position to 40.05Gy in 15 fractions to the whole breast. In the control arm, a SeB of 10Gy in 4 fractions (negative surgical margins) or 14.88Gy in 6 fractions (transsection) was prescribed. In the experimental arm a SIB of 46.8 or 49.95Gy (negative and positive surgical margins, respectively) was prescribed.
RESULTS: Patient age was the only significantly different parameter between treatment arms with patients in the SIB arm being slightly older. In both arms, 6/83 patients developed moist desquamation. Grade 2/3 dermatitis was significantly more frequent in the SeB arm (38/83vs 24/83 patients, p=0.037). In the SIB and SeB arm, respectively, 36 patients (43%) and 51 patients (61%) developed pruritus (p=0.015). The incidence of oedema was lower in the SIB arm (59vs 68 patients), but not statistically significant (p=0.071).
CONCLUSIONS: The primary endpoint, moist desquamation, was not significantly different between treatment arms.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Hypofractionation; Prone; Simultaneous integrated boost; Whole-breast irradiation

Mesh:

Year:  2017        PMID: 28062087     DOI: 10.1016/j.radonc.2016.12.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Radiodermatitis and Fibrosis in the Context of Breast Radiation Therapy: A Critical Review.

Authors:  Sofiane Allali; Youlia Kirova
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

2.  Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial.

Authors:  Sanjoy Chatterjee; Santam Chakraborty
Journal:  Trials       Date:  2020-09-30       Impact factor: 2.279

3.  Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer.

Authors:  David Krug; Christine Köder; Matthias F Häfner; Nathalie Arians; Semi B Harrabi; Stefan A Koerber; Tobias Forster; Ingmar Schlampp; Christof Sohn; Joerg Heil; Holger Hof; Juliane Hörner-Rieber; Jürgen Debus
Journal:  Radiat Oncol       Date:  2020-10-13       Impact factor: 3.481

4.  Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.

Authors:  David Krug; René Baumann; Katja Krockenberger; Reinhard Vonthein; Andreas Schreiber; Alexander Boicev; Florian Würschmidt; Evelyn Weinstrauch; Kirsten Eilf; Peter Andreas; Ulrike Höller; Stefan Dinges; Karen Piefel; Jörg Zimmer; Kathrin Dellas; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-10-01       Impact factor: 3.621

5.  A comparative study on hypofractionated whole-breast irradiation with sequential or simultaneous integrated boost on different positions after breast-conserving surgery.

Authors:  Ting Yu; Yankang Li; Tao Sun; Min Xu; Wei Wang; Qian Shao; Yingjie Zhang; Jianbin Li; Jinming Yu
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.